Any current/future new fundraising through debt or equity?

The company has utilized IPO proceeds for acquisitions and repaid all external borrowings, indicating no immediate new debt. Working capital and CAPEX usage so far is lower than expected, with about ₹135 crores used, expected to reach ₹190 crores by year-end and another ₹100 crores next financial year. There is no mention of any current plans for new fundraising via debt or equity. The company has excess capacity and therefore no immediate need for substantial CAPEX expansion that would require new funding. Overall, no specific current or future fundraising through debt or equity is indicated

Any current/future capex/capital investment/strategic investment?

The company has excess capacity currently and does not foresee a need for substantial CAPEX expansion at the moment. Incremental CAPEX additions are planned during the year and will be communicated as funds are utilized. About ₹190 crores of IPO proceeds are expected to be used for working capital by the end of the year, with another ₹100 crores reserved for the next financial year's working capital requirements. 10% of the IPO proceeds were earmarked for inorganic growth, a portion of which has already been used for acquisitions, including the Altek acquisition. Supply chain synergies are bei

Future growth expectations in sales/revenue/volumes?

The company is executing to a confident plan with ongoing improvements across areas. Significant opportunities are in the pipeline, including three large deals in advanced negotiation stages expected to impact revenue in the next 2 fiscal years. Altek acquisition is expanding the footprint in North America, expected to drive higher growth due to demand for local manufacturing and political trends favoring "Made in U.S." Aerospace and defense remain dominant sectors, but growth is also expected from industrial and medical sectors, leveraging Altek’s expertise. Order book execution timeline vari

Future growth expectations in earnings/operating earnings/profits/EPS?

Company aims for a consistent 10% EBITDA margin as an initial milestone with aspirations to grow beyond that (Page 12). Margins expected to improve in Q4 and beyond due to favorable business mix and ramp down of low-margin large deals (Page 13). EBITDA margins for Altek business are similar currently but have a roadmap to achieve about 10% sustainably (Page 9). Operating expenses impacted by one-off costs (M&A expenses, ECL provisions) that will not repeat, leading to better operating earnings going forward (Page 13, 18). Order book discussions indicate conversion of several large deals in the

Current/ Expected Orderbook/ Pending Orders?

Consolidated order backlog stands at ₹2,142.9 crore, including ₹291.5 crore from Altek. Standalone order backlog (excluding Altek) is approximately ₹1,850 crore. Execution timeline for new POs varies: 9-12 months from PO to meaningful revenue; overall execution spans 18-24 months depending on client needs. Altek has a shorter sales cycle with 50-60% visibility at the start. Some large deals are in advanced negotiation, but specifics on deal quantum remain undisclosed; large deals expected to impact FY 2026 and beyond. Order backlog has seen some decline due to consumption of existing

IN US

Sale is live|00:00:00left today

Cyient DLM LtdQ4 FY26Aerospace & Defense

Cyient DLM Ltd Q4 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹462P/E: 45.1Market Cap: ₹3.3K CrSector: Aerospace & Defense

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→The company is executing to a confident plan with ongoing improvements across areas.
→Significant opportunities are in the pipeline, including three large deals in advanced negotiation stages expected to impact revenue in the next 2 fiscal years.
→Altek acquisition is expanding the footprint in North America, expected to drive higher growth due to demand for local manufacturing and political trends favoring "Made in U.S."
→Aerospace and defense remain dominant sectors, but growth is also expected from industrial and medical sectors, leveraging Altek’s expertise.
→Order book execution timeline varies between 9-12 months for new POs, with overall backlog spread over 18-24 months.
→While short-term growth may vary due to program timing and order consumption rates, the medium to long-term outlook aims for around 30% CAGR with potential margin improvements.
→FY '26 is expected to see revenue impact from current new orders and transfers ramping up progressively.

Margin guidance

Category 3

→Company aims for a consistent 10% EBITDA margin as an initial milestone with aspirations to grow beyond that (Page 12).
→Margins expected to improve in Q4 and beyond due to favorable business mix and ramp down of low-margin large deals (Page 13).
→EBITDA margins for Altek business are similar currently but have a roadmap to achieve about 10% sustainably (Page 9).
→Operating expenses impacted by one-off costs (M&A expenses, ECL provisions) that will not repeat, leading to better operating earnings going forward (Page 13, 18).
→Order book discussions indicate conversion of several large deals in the next 1-2 years, which will positively impact revenues and profits (Page 8, 18).
→Organic growth expected to ease with some softness in the first half of next financial year, with stronger growth and margin expansion later (Page 13).
→Overall, cautious optimism on steady revenue growth and margin improvement over coming quarters.

3 more insights locked — sign up free to unlock

Fundraise plans

→The company has utilized IPO proceeds for acquisitions and repaid all external borrowings, indicating no immediate new debt.
→Working capital and CAPEX usage so far is lower than expected, with about ₹135 crores used, expected to reach ₹190 crores by year-end and another ₹100 crores next financial year.
→There is no mention of any current plans for new fundraising via debt or equity.
→The company has excess capacity and therefore no immediate need for substantial CAPEX expansion that would require new funding.
→Overall, no specific current or future fundraising through debt or equity is indicated in the document.

Order book

→Consolidated order backlog stands at ₹2,142.9 crore, including ₹291.5 crore from Altek.
→Standalone order backlog (excluding Altek) is approximately ₹1,850 crore.
→Execution timeline for new POs varies: 9-12 months from PO to meaningful revenue; overall execution spans 18-24 months depending on client needs.
→Altek has a shorter sales cycle with 50-60% visibility at the start.
→Some large deals are in advanced negotiation, but specifics on deal quantum remain undisclosed; large deals expected to impact FY 2026 and beyond.
→Order backlog has seen some decline due to consumption of existing large orders but a strong pipeline above $1 billion in B2B opportunities is being pursued.
→No significant new client advances expected soon; free cash flow positive this quarter.
→Challenges include timing shifts in awards and extended sales cycles typical of aerospace & defense sectors.

Capex plans

Yes

→The company has excess capacity currently and does not foresee a need for substantial CAPEX expansion at the moment.
→Incremental CAPEX additions are planned during the year and will be communicated as funds are utilized.
→About ₹190 crores of IPO proceeds are expected to be used for working capital by the end of the year, with another ₹100 crores reserved for the next financial year's working capital requirements.
→10% of the IPO proceeds were earmarked for inorganic growth, a portion of which has already been used for acquisitions, including the Altek acquisition.
→Supply chain synergies are being explored to add value, including key components and distribution spend optimization.

How does Cyient DLM Ltd rank vs peers in Aerospace & Defense?

Pro feature

1Cyient DLM Ltd

Rev 3Mar 3

See full Aerospace & Defense sector rankings

Want more stocks like Cyient DLM Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio